Product line architecture recovery with outlier filtering in software families: the Apo-Games case study

Software product line (SPL) approach has been widely adopted to achieve systematic reuse in families of software products. Despite its benefits, developing an SPL from scratch requires high up-front investment. Because of that, organizations commonly create product variants with opportunistic reuse approaches (e.g., copy-and-paste or clone-and-own). However, maintenance and evolution of a large number of product variants is a challenging task. In this context, a family of products developed opportunistically is a good starting point to adopt SPLs, known as extractive approach for SPL adoption. One of the initial phases of the extractive approach is the recovery and definition of a product line architecture (PLA) based on existing software variants, to support variant derivation and also to allow the customization according to customers’ needs. The problem of defining a PLA from existing system variants is that some variants can become highly unrelated to their predecessors, known as outlier variants. The inclusion of outlier variants in the PLA recovery leads to additional effort and noise in the common structure and complicates architectural decisions. In this work, we present an automatic approach to identify and filter outlier variants during the recovery and definition of PLAs. Our approach identifies the minimum subset of cross-product architectural information for an effective PLA recovery. To evaluate our approach, we focus on real-world variants of the Apo-Games family. We recover a PLA taking as input 34 Apo-Game variants developed by using opportunistic reuse. The results provided evidence that our automatic approach is able to identify and filter outlier variants, allowing to eliminate exclusive packages and classes without removing the whole variant. We consider that the recovered PLA can help domain experts to take informed decisions to support SPL adoption.This research was partially funded by INES 2.0; CNPq grants 465614/2014-0 and 408356/2018-9; and FAPESB grants JCB0060/2016 and BOL2443/201

Efficacy of Combined Therapy with Amantadine, Oseltamivir, and Ribavirin In Vivo against Susceptible and Amantadine-Resistant Influenza A Viruses

The limited efficacy of existing antiviral therapies for influenza – coupled with widespread baseline antiviral resistance – highlights the urgent need for more effective therapy. We describe a triple combination antiviral drug (TCAD) regimen composed of amantadine, oseltamivir, and ribavirin that is highly efficacious at reducing mortality and weight loss in mouse models of influenza infection. TCAD therapy was superior to dual and single drug regimens in mice infected with drug-susceptible, low pathogenic A/H5N1 (A/Duck/MN/1525/81) and amantadine-resistant 2009 A/H1N1 influenza (A/California/04/09). Treatment with TCAD afforded >90% survival in mice infected with both viruses, whereas treatment with dual and single drug regimens resulted in 0% to 60% survival. Importantly, amantadine had no activity as monotherapy against the amantadine-resistant virus, but demonstrated dose-dependent protection in combination with oseltamivir and ribavirin, indicative that amantadine's activity had been restored in the context of TCAD therapy. Furthermore, TCAD therapy provided survival benefit when treatment was delayed until 72 hours post-infection, whereas oseltamivir monotherapy was not protective after 24 hours post-infection. These findings demonstrate in vivo efficacy of TCAD therapy and confirm previous reports of the synergy and broad spectrum activity of TCAD therapy against susceptible and resistant influenza strains in vitro